Mortality Reduction with Low-Dose CT Screening for Lung Cancer

Since the publication of the first mortality results from the National Lung Screening Trial (NLST), which showed a 20% reduction in lung-cancer mortality with low-dose computed tomographic (CT) screening,1 the intervention has been adopted as policy in the United States, and there has been considerable discussion of the possibilities for its adoption in Europe.2,3 Policy decisions are still awaited in many countries, despite the unequivocal nature of the original NLST results.1 This is likely to be partly due to doubts fostered by the early publication of inconclusive results of a number of smaller trials in Europe.4,5 These doubts should be . . .